TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE

Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided. 2. The compound of claim 1 , wherein m and n are both 1.3. The compound of claim 1 , wherein m is 2 and n is 1.4. The compound of claim 1 , wherein X is hydrogen.5. The compound of claim 1 , wherein X is (C-C)alkyl.6. The compound of claim 5 , wherein X is methyl or ethyl.7. The compound of claim 1 , wherein Y and Z are both halogen.8. The compound of claim 7 , wherein Y and Z are both chloride.9. The compound of claim 1 , wherein the compound is stereomerically pure.11. A pharmaceutical composition comprising a compound of .12. The pharmaceutical composition of claim 11 , which further comprises one or more additional active agents.13. A method of inhibiting binding of a monoamine transporter ligand to a monoamine transporter claim 1 , said method comprising contacting said monoamine transporter and a compound of .14. A method of inhibiting the activity of at least one monoamine transporter claim 1 , said method comprising contacting said monoamine transporter and a compound of .15. The method of or claim 1 , wherein said monoamine transporter is a serotonin transporter (SERT) claim 1 , a dopamine transporter (DAT) claim 1 , a norepinephrine transporter (NET) claim 1 , or a combination thereof.16. The method of claim 14 , wherein said compound inhibits the activity of at least two different monoamine transporters.17. A method of inhibiting uptake of at least one monoamine by a cell claim 1 , said method comprising contacting said cell and a compound of .18. The method of claim 17 , wherein said monoamine is ...

Electric-regenerative solar energy assisted sludge biodrying system

The invention relates to an electric-regenerative solar energy assisted sludge biodrying system. The system comprises a solar heat collector, and a solar greenhouse I and a solar greenhouse II which are adjacently arranged, a circulating pump, a heat storage device, a drying device, a fermentation bed and a ventilation device are arranged in the solar greenhouse I, a drying device, a drying bed and a ventilation device are arranged in the solar greenhouse II, a material discharging hole is arranged between the solar greenhouse I and the solar greenhouse II, and a material convey belt under the fermentation bed in the solar greenhouse I conveys mixed sludge obtained after fermentation to the drying bed in the solar greenhouse II through the material discharging hole. Compared with the prior art, the electric-regenerative solar energy assisted sludge biodrying system which utilizes the solar energy to assist drying enables the industrial biodrying treatment of the sludge to be continuously ...

Method for operating intelligent secret key equipment

The invention discloses a method for operating intelligent secret key equipment, and belongs to the field of information security. The method includes electrifying and initializing the equipment; enabling the equipment to read parameters of a Bluetooth module, judging whether the parameters of the Bluetooth module can be successfully read or not, switching the Bluetooth module into a connection state and executing a next step if the parameters of the Bluetooth module can be successfully read, or directly executing the next step if the parameters of the Bluetooth module cannot be successfully read; enabling the equipment to judge whether the operating voltage is lower than a preset value or not, prompting a low-voltage state and shutting down the equipment in preset time if the operating voltage is lower than the preset value, or enabling the equipment to continuously detect the operating voltage and wait for an interrupt trigger signal if the operating voltage is not lower than the preset ...

Method for improving anaerobic energy production efficiency of algae raw material through bacterial degradation biological pretreatment

The invention belongs to the field of biotechnology and renewable energy sources, and relates to a method for improving the anaerobic energy production efficiency of an algae raw material through bacterial degradation biological pretreatment. The method comprises the following steps: (1), the algae raw material is mixed with a nutritive salt solution to be inoculated to an anaerobic cellulose degrading bacteria seed solution which is cultivated in advance; (2), the seed solution is cultivated under the conditions of thermal insulation and opaque background, the bacterial degradation pretreatment is performed, hydrogen is synchronously produced, hydrolysis of cell walls is promoted, and hydrogen, hydrolysis product ethanol and volatile organic acid are obtained; and (3), after the bacterial degradation synchronous hydrogen production cultivation is finished, anaerobic inoculated sludge containing methanogens is inoculated in fermentation liquor, and accordingly hydrolysis product ethanol ...

Method for controlling anaerobic digestion of easily-degradable organic wastes through utilizing intermittent micro-aeration

The invention relates to a method for controlling the anaerobic digestion of easily-degradable organic wastes through utilizing intermittent micro-aeration. The method comprises the following steps: installing a micro-aeration apparatus at the bottom of an anaerobic digestion reactor; carrying out intermittent micro-aeration treatment of the anaerobic digestion reactor; stopping the intermittent micro-aeration after the anaerobic digestion process runs well and methane is stably produced; and carrying out intermittent micro-aeration of the anaerobic digestion reactor again if an acid inhibition phenomenon or an ammonia nitrogen inhibition phenomenon appears in the anaerobic digestion process. Compared with the prior art, the method provided by the invention, which allows the easily-degradable organic wastes to undergo intermittent micro-aeration in the anaerobic digestion process, utilizes excess organic acids generated in the hydrolysis acidifying process of anaerobic bacteria to maintain ...

UV-near infrared quantum cutting phosphor and preparation method thereof

The invention discloses a UV-near infrared quantum cutting phosphor and preparation method thereof. The molecular formula of the quantum cutting phosphor is LaBO3: xCe3+, yYb3+, wherein, 0.01<=x<=0.3, 0.005<=y<=0.1. Under the reduction condition, the mixture of lanthana, cerium oxide, ytterbium oxide and boric acid are pre-sintered and sintered in order, and the UV-near infrared quantum cutting phosphor is obtained. The phosphor provide by the invention does not shine in the visible light range, and is used for the aspects of novel false proof technology as well as military and common safety, and the phosphor can be excited by 365nm ultraviolet light without damage for human body, and is convenient for popularization and application.

Method for in-situ determination of wood fiber biomass enzyme accessibility

The invention belongs to the field of environmental biological energy and relates to a method for in-situ determination of cellulase accessibility of wood fiber biomass. The method comprises the following steps of: 1) marking general enzyme binding sites of a wood fiber biomass sample; 2) in-situ observing the distribution and the quantity of the general enzyme binding sites, and calculating to obtain the quantity of fiber globule fluorescent protein probes which are attached onto the surface of the sample; 3) releasing the general enzyme binding sites; 4) closing the sample obtained in the step 3 by using lignin attachment proteins, and marking the cellulase binding sites in the sample to obtain the distribution and the quantity of the cellulase binding sites and the quantity of the fiber globule fluorescent protein probes which are attached onto the surface of the sample; and 5) comparing results of the step 4 and the step 2, and evaluating the cellulase accessibility of the wood fiber ...

Sludge discharge field constructing method for speeding up dehydration, solidification and stabilization of dredged sediment

The invention relates to a sludge discharge field constructing method for speeding up dehydration, solidification and stabilization of dredged sediment. The method comprises the following steps of: paving a strengthened drainage layer on each inner side slope of a cofferdam around the sludge discharge field, wherein a drainage collecting pipe is arranged at the bottom of each strengthened drainage layer to form a side slope drainage system; and arranging upright drainage walls in the middle of the sludge discharge field, wherein drainage collecting pipes are arranged below the drainage walls to form a drainage wall drainage system, namely the side slope drainage system and the drainage wall drainage system are constructed to speed up the dehydration, solidification and stabilization of the dredged sediment of the sludge discharge field. Compared with the prior art, the upper layer of clear liquid of sludge is discharged through a recession pool, and the water in the sludge is discharged ...

Integrated homogenizing process of prehydrolysis and mechanical disruption of biomass garbage

The invention discloses an integrated homogenizing process of prehydrolysis and mechanical disruption of biomass garbage. The integrated homogenizing process comprises the following specific steps of: placing biomass garbage raw materials in a hydrolyzing tank, after prehydrolysis, impurity removing, mechanical disruption homogenizing and solid-liquid separation, carrying out enzyme regulation on filter liquor and applying the filter liquor for a prehydrolysis link in a recycling way, and placing concentrated homogeneous biomass into subsequent processes to be subjected to anaerobic digestion processing. Through the process, the filter liquor after being subjected to the enzyme regulation is recharged into the biomass garbage, the prehydrolysis degree of the materials can be improved, and the prehydrolysis process can be accelerated; the shearing strength of the biomass garbage after being subjected to the prehydrolysis can be substantially reduced, and thus, the energy consumption in the ...

Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors

Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

Triple reuptake inhibitors and methods of their use

Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Working method of smart key device

A working method of a smart key device, in which it includes: power on the smart key device; the smart key device reads Bluetooth module parameters, and determines whether the Bluetooth module parameters are read successfully, if the parameters are read successfully, switch the Bluetooth module to connection state, and execute a next step; if the parameters are not read successfully, execute the next step directly; the smart key device determines whether working voltage is lower than a preset value, if yes, prompt low voltage state, and the device is turned off after a first preset time; if no, the device tests working voltage and waits for an interrupt trigger signal; when the device receives the interrupt trigger signal, enter corresponding interruption according to the interrupt trigger signal, after execute corresponding interrupt processing, exit corresponding interruption and continue to test the working voltage. The present invention can unify interfaces of mobile devices, so as to make mobile payment safer and more convenient.

Working method of dynamic token

The invention discloses a working method of a dynamic token, and relates to the field of communication. The method comprises the steps that when the dynamic token is awakened, the awakening identification types of a set are judged, and if the set is key awakening identification, key values are detected, and corresponding operation is executed according to pressed keys; if the set is Bluetooth data awakening identification, Bluetooth data are received, and when the Bluetooth data are received, the Bluetooth data are stored in a data receiving cache region, and the Bluetooth data awakening identification is reset; if the set is Bluetooth connection awakening identification, a Bluetooth connection state is displayed, and after fourth preset time is delayed, a screen is cleared, and the Bluetooth connection awakening identification is reset; if the set is Bluetooth disconnection awakening identification, a Bluetooth disconnection state is displayed, the data receiving cache region is cleared ...

Method for improving anaerobic digestion performance of sludge and synchronously enlarging cultivation by functional bacteria

The invention relates to a method for improving anaerobic digestion performance of sludge and synchronously enlarging cultivation by functional bacteria. The method comprises the following steps of: collecting and screening the functional bacteria; enlarging cultivation of the functional bacteria; preparing functional bacteria solution; inoculating the functional bacteria solution into an anaerobic digestion reactor containing sludge after carrying out anaerobic digestion for 10-15 days on the sludge, further carrying out anaerobic digestion on the sludge for 15-30 days, hydrolyzing protein which is difficult to degrade in the sludge into low molecular weight organic matters by the functional bacteria; hydrolyzing the low molecular weight organic matters to form methane by mathanogenic bacteria; and carrying out multiplication of bacteria cells by the functional bacteria, so as to finally obtain sludge digestion residue containing the methanogenic bacteria and the functional bacteria. Compared ...

Multicyclic compounds and methods of use thereof

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Pyrrolidine triple reuptake inhibitors

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Working method of dynamic token

The invention discloses a working method of a dynamic token, relating to the field of communication. The method comprises the following steps: when the token is awaken, judging a set awakening identifier type; if an awakening identifier is a key awakening identifier, detecting a key value and executing corresponding operation according to a pressed key; if the awakening identifier is a Bluetooth data awakening identifier, receiving Bluetooth data, saving the Bluetooth data in a received data buffer region after the Bluetooth data are received, and resetting the Bluetooth data awakening identifier; if the awakening identifier is a Bluetooth connection awakening identifier, displaying that Bluetooth is connected, delaying for a fourth preset time period, clearing, and resetting the Bluetooth connection awakening identifier; if the awakening identifier is a Bluetooth disconnection awakening identifier, displaying that Bluetooth is disconnected, clearing the received data buffer region, and ...

Cycloalkylamines as monoamine reuptake inhibitors

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Pyrrolidine triple reuptake inhibitors

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia. 24-. (canceled)6. The compound of claim 5 , wherein m is 0; n is 1; Rand Rare each independently hydrogen claim 5 , optionally substituted C-Calkyl claim 5 , or optionally substituted C-Calkyl; Rand Rare each independently hydrogen or optionally substituted C-Calkyl; Ris hydrogen; and Rand Rare each independently hydrogen claim 5 , halo claim 5 , C-Calkyl claim 5 , aryl claim 5 , heteroaryl claim 5 , heterocyclyl claim 5 , alkoxyl claim 5 , or aminoalkyl claim 5 , each of which is optionally substituted.7. (canceled)8. The compound of claim 5 , wherein Rand Rtogether with the nitrogen atom to which they are attached form a heteroaryl or heterocyclyl claim 5 , each of which is optionally substituted.9. (canceled)10. The compound of claim 5 , wherein Rand Rtogether with the atoms to which they are attached form an optionally substituted heterocyclyl ring.11. (canceled)12. The compound of claim 5 , wherein Rand Rtogether with the atom to which they are attached form a cycloalkyl or heterocyclyl ring claim 5 , each of which is optionally substituted.13. (canceled)14. The compound of claim 5 , wherein Rand Rtogether with the atoms to which they are attached form an aryl or cycloalkyl ring claim 5 , each of which is optionally substituted.15. (canceled)16. The compound of claim 5 , wherein Rand Rtogether with the atoms to which they are attached form an optionally substituted heterocyclyl.17. (canceled)18. The compound of claim 5 , wherein Rand Rtogether with the atoms to which they are attached form an optionally substituted heterocyclyl and Rand Rtogether with the nitrogen atom to which they are attached form an optionally substituted aryl. ...

PYRROLIDINE TRIPLE REUPTAKE INHIBITORS

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. 131-. (canceled)44. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.45. A method of inhibiting binding of a monoamine transporter ligand to a monoamine transporter claim 32 , comprising contacting the monoamine transporter with a compound of .46. The method of claim 45 , wherein the monoamine transporter is selected from serotonin transporter (SERT) claim 45 , dopamine transporter (DAT) claim 45 , norepinephrine transporter (NET) and combinations thereof.47. A method of inhibiting the activity of at least one monoamine transporter claim 32 , comprising contacting the monoamine transporter with a compound of .48. The method of claim 47 , wherein the monoamine transporter is selected from serotonin transporter (SERT) claim 47 , dopamine transporter (DAT) claim 47 , norepinephrine transporter (NET) and combinations thereof.49. A method of inhibiting uptake of at least one monoamine by a cell claim 32 , comprising contacting said cell with a compound of .50. The method of claim 49 , wherein the monoamine is selected from serotonin claim 49 , dopamine claim 49 , norepinephrine and combinations thereof.51. The method of claim 49 , wherein the cell is a neuronal cell.52. A method of treating a central nervous system disorder claim 32 , comprising administering to a subject in need thereof ...

PYRROLIDINE TRIPLE REUPTAKE INHIBITORS

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. 130-. (canceled)32. The compound of or a pharmaceutically acceptable salt claim 31 , solvate claim 31 , enantiomer claim 31 , diastereomer claim 31 , racemic mixture claim 31 , enantiomerically enriched mixture claim 31 , or enantiomerically pure form thereof claim 31 , wherein Ar is phenyl substituted with at least one chloro.34. The compound according to or a pharmaceutically acceptable salt claim 33 , solvate enantiomer claim 33 , diastereomer claim 33 , racemic mixture claim 33 , enantiomerically enriched mixture claim 33 , or enantiomerically pure form thereof claim 33 , wherein each of Xand Xis independently halogen.35. The compound according to or a pharmaceutically acceptable salt claim 34 , solvate enantiomer claim 34 , diastereomer claim 34 , racemic mixture claim 34 , enantiomerically enriched mixture claim 34 , or enantiomerically pure form thereof claim 34 , wherein each of Xand Xis Cl.42. A pharmaceutical composition comprising a compound of claim 31 , or a pharmaceutically acceptable salt claim 31 , solvate enantiomer claim 31 , diastereomer claim 31 , racemic mixture claim 31 , enantiomerically enriched mixture claim 31 , or enantiomerically pure form thereof claim 31 , and a pharmaceutically acceptable carrier.43. A method of inhibiting the activity of at least one monoamine transporter claim 31 , the method ...

METHOD FOR REMOVING CALCIUM IONS FROM HIGH CONCENTRATION ORGANIC WASTEWATER

A method for removing calcium ions from high concentration organic wastewater is provided. The method comprises the steps of: (1) introducing high concentration organic wastewater containing Ca, inorganic carbon and a seed crystal into a reactor with a molar ratio of Ca to inorganic carbon of 1:(3.2-6.2); (2) adjusting the hydrogen ion activity α(H) and ionic strength of the solution in the reactor; (3) sequentially stirring and precipitating in the reactor to convert Ca in the high concentration organic wastewater into calcium carbonate which is then precipitated for calcium removal. 1. A method for removing calcium ions from high concentration organic wastewater , wherein the method comprises the steps of:{'sup': 2+', '+, '(1) introducing high concentration organic wastewater containing Ca, inorganic carbon and a seed crystal into a reactor with a molar ratio of Ca to inorganic carbon of 1:(3.2-6.2);'}{'sup': '+', '(2) adjusting a hydrogen ion activity α(H) and ionic strength of the solution in the reactor;'}{'sup': '2+', '(3) sequentially stirring and precipitating in the reactor to convert Ca in the high concentration organic wastewater into calcium carbonate which is then precipitated for calcium removal.'}2. The method for removing calcium ions from high concentration organic wastewater according to claim 1 , wherein a COD and Ca concentration of the high concentration organic wastewater in step (1) is more than 2000 mg/L and more than 500 mg/L claim 1 , respectively.3. The method for removing calcium ions from high concentration organic wastewater according to claim 1 , wherein the inorganic carbon in step (1) is a kind of liquid or soluble solid that can directly release the inorganic carbon.4. The method for removing calcium ions from high concentration organic wastewater according to claim 1 , wherein the seed crystal in step (1) is biomass with negative potential on a surface.5. The method for removing calcium ions from high concentration organic ...

Triple reuptake inhibitors and methods of their use

Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit re-uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Heteroaryl Compounds and Methods of Use Thereof

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia. 2. The compound of claim 1 , wherein one of Rand Ris selected from a dihydropyrimidine claim 1 , dihydroquinazoline claim 1 , and a pyrimidine group.3. The compound of wherein one of Rand Ris selected from a 1 claim 2 ,6-dihydropyrimidine claim 2 , 1 claim 2 ,4-dihydropyrimidine claim 2 , and a pyrimidine.4. The compound of claim 2 , wherein on of Rand Ris selected from a dihydropyrimidine claim 2 , and a pyrimidine group; and the other of Rand Ris selected from hydrogen claim 2 , halo claim 2 , cyano claim 2 , alkyl claim 2 , alkoxyl claim 2 , alkenyl claim 2 , alkynyl claim 2 , cycloalkyl claim 2 , cycloalkylalkyl claim 2 , aryl claim 2 , and aralkyl; or{'sup': 1a', '1b', '2, 'Ris selected from a dihydropyrimidine and a pyrimidine group; and taken together, Rand Rand the atoms to which they are attached form a cycloalkyl, aryl, heterocyclic or heteroaryl ring.'}7. The compound of claim 6 , wherein Rand Rare each independently selected from hydrogen claim 6 , halo claim 6 , cyano claim 6 , amino claim 6 , alkylamino claim 6 , alkyl claim 6 , alkoxyl claim 6 , alkenyl claim 6 , alkynyl claim 6 , cycloalkyl claim 6 , and aryl.10. The compound of claim 6 , wherein Rand Rtogether with the atoms to which they are attached form an aryl claim 6 , cycloalkyl claim 6 , heterocyclyl claim 6 , or heteroaryl ring.22. The compound of claim 21 , wherein Rand Rare each independently selected from hydrogen claim 21 , halo claim 21 , cyano claim 21 , amino claim 21 , alkylamino claim 21 , alkyl claim 21 , alkoxyl claim 21 , alkenyl claim 21 , alkynyl claim 21 , cycloalkyl claim 21 , and aryl.24. The compound of claim 22 , wherein Ris hydrogen or alkyl; ...

Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors

Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia. 2. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein m is 0.3. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein n is 1.4. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rare each independently hydrogen claim 1 , fluoro claim 1 , chloro claim 1 , methyl claim 1 , CF claim 1 , ethyl claim 1 , propyl claim 1 , isopropyl claim 1 , phenyl claim 1 , pyridyl claim 1 , pyrrolidinyl claim 1 , piperidinyl claim 1 , morpholinyl claim 1 , methoxyl claim 1 , or dimethylamino.5. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen.6. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rtogether with the atoms to which they are attached form an optionally substituted pyrrolidinyl; and Ris hydrogen or alkyl.7. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rtogether form a double bond and together with Rand the atoms to which they are attached form an optionally substituted imidazoyl claim 1 , pyrazolyl claim 1 , or thiazolyl.8. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rtogether with the atoms to which they are attached form an optionally substituted heterocyclyl; and Ris hydrogen or alkyl.9. The compound of claim 8 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 8 , wherein Ris hydrogen.10. The compound ...

PYRROLIDINE TRIPLE REUPTAKE INHIBITORS

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. 2. The compound according to wherein Ar is selected from phenyl substituted with at least one halogen claim 1 , and unsubstituted naphthyl.3. The compound according to wherein said at least one halogen is chloro.611-. (canceled)12. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.1320-. (canceled)21. A method of treating depression comprising administering to a subject in need thereof a therapeutically effective amount of a compound of .2223-. (canceled)24. A method of treating a central nervous system disorder claim 1 , said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of .25. (canceled)26. The method of wherein said central nervous system disorder is selected from the group consisting of depression claim 24 , cognitive deficit claim 24 , fibromyalgia claim 24 , pain claim 24 , sleep disorder claim 24 , attention deficit disorder (ADD) claim 24 , attention deficit hyperactivity disorder (ADHD) claim 24 , restless leg syndrome claim 24 , schizophrenia claim 24 , anxiety claim 24 , obsessive compulsive disorder claim 24 , posttraumatic stress disorder claim 24 , premenstrual dysphoria claim 24 , and neurodegenerative disease.27. The method according to wherein said depression is selected from the group consisting of ...

WORKING METHOD OF SMART KEY DEVICE

A working method of a smart key device, in which it includes: power on the smart key device; the smart key device reads Bluetooth module parameters, and determines whether the Bluetooth module parameters are read successfully, if the parameters are read successfully, switch the Bluetooth module to connection state, and execute a next step; if the parameters are not read successfully, execute the next step directly; the smart key device determines whether working voltage is lower than a preset value, if yes, prompt low voltage state, and the device is turned off after a first preset time; if no, the device tests working voltage and waits for an interrupt trigger signal; when the device receives the interrupt trigger signal, enter corresponding interruption according to the interrupt trigger signal, after execute corresponding interrupt processing, exit corresponding interruption and continue to test the working voltage. The present invention can unify interfaces of mobile devices, so as to make mobile payment safer and more convenient. 1. A working method of a smart key device , characterized in that said method comprises:Step S1, powering on the smart key device so as to start initialization;Step S2, reading, by the smart key, Bluetooth module parameters, determining whether the Bluetooth module parameters are successfully read, if yes, switching the Bluetooth to a connection state and executing S3, otherwise executing step S3;Step S3, determining, by the smart key device, whether its working voltage is lower than a preset value, if yes, prompting low voltage state and turning off the smart key device after a first preset time; otherwise, continuing to execute Step S3;when an interrupt trigger signal which is received by the smart key device is a channel trigger signal, entering corresponding interruption of a channel trigger, and exiting the corresponding interruption of the channel trigger after executing corresponding setting of the channel trigger, and returning ...

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia. 242-. (canceled)42. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable excipient or carrier.43. A method of treating a neurological disorder claim 1 , comprising administering to a subject a therapeutically or prophylactically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.44. The method of claim 44 , wherein the disorder is schizophrenia claim 44 , schizophrenia spectrum disorder claim 44 , acute schizophrenia claim 44 , chronic schizophrenia claim 44 , NOS schizophrenia claim 44 , schizoid personality disorder claim 44 , schizotypal personality disorder claim 44 , delusional disorder claim 44 , psychosis claim 44 , psychotic disorder claim 44 , brief psychotic disorder claim 44 , shared psychotic disorder claim 44 , psychotic disorder due to a general medical condition claim 44 , drug-induced psychosis claim 44 , psychoaffective disorder claim 44 , aggression claim 44 , delirium claim 44 , Parkinson's psychosis claim 44 , excitative psychosis claim 44 , Tourette's syndrome claim 44 , organic or NOS psychosis claim 44 , seizure claim 44 , agitation claim 44 , post-traumatic stress disorder claim 44 , behavior disorder claim 44 , neurodegenerative disease claim 44 , Alzheimer's disease claim 44 , Parkinson's disease claim 44 , dyskinesias claim 44 , Huntington's disease claim 44 , dementia claim 44 , mood disorder claim 44 , anxiety claim 44 , affective disorder claim 44 , depression claim 44 , major depressive disorder claim 44 , dysthymia claim 44 , bipolar disorder claim 44 , manic disorder; ...

CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. 2. The compound according to claim 1 , wherein said compound is chiral.5. The compound according to claim 4 , wherein X′ and Xare members independently selected from the group consisting of H claim 4 , methyl claim 4 , ethyl claim 4 , n-propyl claim 4 , OH claim 4 , OMe claim 4 , OEt claim 4 , F claim 4 , Cl claim 4 , CN claim 4 , CHOH claim 4 , CHOMe claim 4 , and CF.6. The compound according to claim 4 , wherein Ris H or substituted or unsubstituted C-Calkyl.7. The compound according to claim 4 , wherein Rand Rare members independently selected from the group consisting of substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl.8. The compound according to claim 3 , wherein Ar is a member selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted naphthyl.10. The compound of claim 9 , wherein Y claim 9 , Z claim 9 , Yand Zare members independently selected from the group consisting of H claim 9 , CF claim 9 , OR claim 9 , SR claim 9 , OCF claim 9 , halogen and CN.12. A composition comprising a first stereoisomer and at least one additional stereoisomer of a compound according to claim 1 , wherein said first stereoisomer is present in a diastereomeric excess of at least 80% relative to said at least one additional stereoisomer.13. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.14. A method of inhibiting ...

METHOD OF INHIBITING FORMATION OF DIOXINS AND DIOXIN-LIKE COMPOUNDS IN SOLID WASTE INCINERATION FLUE GAS

The present invention relates to a method for inhibiting the formation of dioxin-like compounds in solid waste incineration flue gases, belonging to the field of cleaning of solid waste incineration flue gases. In accordance with the present invention, when incineration flue gases cool down to 500˜450° C., the flue gases are introduced into an inhibition reactor where copper chlorides in flue gas particulates mix and react with inhibitors to convert into copper metaphosphate so as to inactivate the copper chlorides which can catalyze the formation of dioxin-like compounds and control dioxin-like compound pollutants in incineration flue gases at the source. Compared with the prior art, the invention can effectively control the main formation ways of dioxin-like compounds in solid waste incineration flue gases by optimizing inhibitors and reaction conditions. The method of the invention does not affect the residual heat utilization of solid waste incineration flue gases, so solid waste incineration has a better resource utilization effect. The ammonium dihydrogen phosphate inhibitor used in the invention has the advantages of high inhibition efficiency, strong operability, low cost and environment protection, providing the technology with good application feasibility. 1. Method of inhibiting formation of dioxins and dioxin-like compounds in solid waste incineration flue gas , characterized in that , when incineration flue gases cool down to 500˜450° C. , the flue gases are introduced into an inhibition reactor where copper chloride in flue gas particulates mix and react with inhibitors to convert into copper metaphosphate.2. The method of inhibiting formation of dioxins and dioxin-like compounds in solid waste incineration flue gas as claimed in claim 1 , characterized in that the inhibition reactor is provided inside with layered ceramic honeycomb packing claim 1 , wherein the thickness of each packing layer is 50˜100 mm claim 1 , the hole opening ratio of packing is ...

MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia. 139-. (canceled)44. A pharmaceutical composition comprising a compound of claim 40 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 40 , and a pharmaceutically acceptable excipient or carrier.45. The pharmaceutical composition of claim 44 , which further comprises one or more additional active agents.46. A method of treating claim 40 , preventing claim 40 , or managing a neurological disorder claim 40 , comprising administering to a subject a therapeutically or prophylactically effective amount of a compound of claim 40 , or a pharmaceutically acceptable salt or stereoisomer thereof.47. The method of claim 46 , wherein said subject is a human.48. The method of claim 46 , wherein the disorder is schizophrenia claim 46 , schizophrenia spectrum disorder claim 46 , acute schizophrenia claim 46 , chronic schizophrenia claim 46 , NOS schizophrenia claim 46 , schizoid personality disorder claim 46 , schizotypal personality disorder claim 46 , delusional disorder claim 46 , psychosis claim 46 , psychotic disorder claim 46 , brief psychotic disorder claim 46 , shared psychotic disorder claim 46 , psychotic disorder due to a general medical condition claim 46 , drug-induced psychosis claim 46 , psychoaffective disorder claim 46 , aggression claim 46 , delirium claim 46 , Parkinson's psychosis claim 46 , excitative psychosis claim 46 , Tourette's syndrome claim 46 , organic or NOS psychosis claim 46 , seizure claim 46 , agitation claim 46 , post-traumatic stress disorder claim 46 , behavior disorder claim 46 , neurodegenerative disease claim 46 , Alzheimer's disease claim 46 , Parkinson's disease claim 46 , dyskinesias claim 46 ...

TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE

Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided. 2. The compound of claim 1 , wherein m and n are both 1.3. The compound of claim 1 , wherein m is 2 and n is 1.4. The compound of claim 1 , wherein X is hydrogen.5. The compound of claim 1 , wherein X is (C-C)alkyl.6. The compound of claim 5 , wherein X is methyl or ethyl.7. The compound of claim 1 , wherein Y and Z are both halogen.8. The compound of claim 7 , wherein Y and Z are both chloride.9. The compound of claim 1 , wherein the compound is stereomerically pure.11. A pharmaceutical composition comprising a compound of .12. The pharmaceutical composition of claim 11 , which further comprises one or more additional active agents.13. A method of inhibiting binding of a monoamine transporter ligand to a monoamine transporter claim 1 , said method comprising contacting said monoamine transporter and a compound of .14. A method of inhibiting the activity of at least one monoamine transporter claim 1 , said method comprising contacting said monoamine transporter and a compound of .15. The method of or claim 1 , wherein said monoamine transporter is a serotonin transporter (SERT) claim 1 , a dopamine transporter (DAT) claim 1 , a norepinephrine transporter (NET) claim 1 , or a combination thereof.16. The method of claim 14 , wherein said compound inhibits the activity of at least two different monoamine transporters.17. A method of inhibiting uptake of at least one monoamine by a cell claim 1 , said method comprising contacting said cell and a compound of .18. The method of claim 17 , wherein said monoamine is ...

Multicyclic Compounds and Methods of Use Thereof

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REPUTAKE INHIBITORS

Phenyl-substituted cyclohexylamine derivatives and methods for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided. 2. The compound of claim 1 , wherein Rand Rare members independently selected front the group consisting of substituted or unsubstituted C-Calkyl and substituted or unsubstituted C-Cheteroalkyl.3. The compound of claim 1 , wherein Rand Rare members independently selected from the group consisting of substituted or unsubstituted alkenyl claim 1 , substituted or unsubstituted alkynyl and substituted or unsubstituted cycloalkyl.6. The compound of claim 4 , wherein Y and X are members independently selected from the group consisting of H claim 4 , halogen claim 4 , CN and CF.7. The compound of claim 6 , wherein Y and X are chloro.8. The compound of claim 7 , wherein s is 1.9. The compound of claim 8 , wherein n is 1.12. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , vehicle or diluent.13. A method for treating or preventing a neurological disorder claim 1 , said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof.14. The method of claim 13 , wherein said neurological disorder is a member selected from the group consisting of substance abuse claim 13 , fibromyalgia claim 13 , pain claim 13 , sleep disorder claim 13 , attention deficit disorder (ADD) claim 13 , attention deficit ...

CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. 2. The compound according to claim 1 , wherein said compound is chiral.5. The compound according claim 4 , to claim 4 , wherein Xand Xare members independently selected from the group consisting of H claim 4 , methyl claim 4 , n-propyl claim 4 , OH claim 4 , OMe claim 4 , OEt claim 4 , F claim 4 , Cl claim 4 , CN claim 4 , CHOH claim 4 , CHOMe claim 4 , and CF.6. The compound according to claim 4 , wherein Ror substituted or unsubstituted C-Calkyl.7. The compound according to claim 4 , wherein Rand Rare members independently selected from the group consisting of substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl.8. The compound according to claim 3 , wherein Ar is a member selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted naphthyl.10. The compound of claim 9 , wherein Y claim 9 , Z claim 9 , Yand Zare members independently selected from the group consisting of H claim 9 , CF claim 9 , OR claim 9 , SROCF claim 9 , halogen of CN.12. A composition comprising a first stereoisomer and at least one additional stereoisomer of a compound according to claim 1 , wherein said first stereoisomer is present in a diastereomeric excess of at least 80% relative to said at least one additional stereoisomer.13. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.14. A method of inhibiting binding ofa monoamine ...

Heteroaryl compounds and methods of use thereof

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

SELF-DEODORIZING COMPOSTING SYSTEM

The present invention relates to a self-deodorizing composting system, comprising an outer membrane, an inner membrane, an air-ribbed cage and a deodorizing base, wherein two deodorizing bases are provided; the outer membrane and the inner membrane are held by the air-ribbed cage, with both ends of the outer membrane and the inner membrane respectively fixed to the two deodorizing bases, whereby a closed space is formed between the outer membrane and the inner membrane; the inner side of the inner membrane is used for placing the composting piles, with the malodor and water vapor generated from the composting piles entering into the closed space formed between the outer membrane and the inner membrane through the inner membrane, so that the water vapor is condensed into the water in the closed space, and the malodor molecules are absorbed and dissolved into the condensed water, thus forming the waste water which falls along the inner side of the outer membrane and the outer side of the inner membrane to the bottom of the deodorizing bases and is discharged from the deodorizing base. Comparing with the prior art, the system in the present invention has a simple and detachable structure, and can isolate and remove the malodor and the water vapor generated when the biomass waste is composted. 1. A self-deodorizing composting system , comprising an outer membrane an inner membrane , an air-ribbed cage and deodorizing bases , wherein two deodorizing bases are provided; the outer membrane and the inner membrane are held by an air-ribbed cage , with both ends of the outer membrane and the inner membrane respectively fixed to the two deodorizing bases; the outer membrane using air-proof and water-proof fabric is located on the outer side of the air-ribbed cage , while the inner membrane using breathable but water-proof fabric is located on the inner side of the air-ribbed cage; the inner side of the inner membrane is used for placing the compost , with the malodor and water ...

Multicyclic compounds and methods of use thereof

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

METHOD AND SYSTEM OF TREATING BIOMASS WASTES BY BIOCHEMISTRY-THERMOCHEMISTRY MULTI-POINT INTERCONNECTION

The present invention discloses a method and a system of treating biomass wastes by biochemistry-thermochemistry multi-point interconnection. The present invention applies solid, gas and liquid products of the thermochemical treatment subsystem to the biochemical treatment subsystem and applies heat produced by the biochemical treatment subsystem to the thermochemical treatment subsystem, forming multi-point and two-way interconnection between the biochemical treatment subsystem and the thermochemical treatment subsystem, thereby increasing the yield and stability of energy gas of the biochemical treatment subsystem and reducing pollution and energy consumption of the thermochemical treatment subsystem respectively. The present invention is suitable for treating biomass wastes with high and low water contents at the same time, producing soil amendment, liquid fuel and biogas, having properties of low secondary pollution and significant reduction of greenhouse gas emission and so on. The bio-stability, humus content and nitrogen content of the solid product are as high as soil amendment, making it easy to store and transport. 1. A method of treating biomass wastes by biochemistry-thermochemistry multi-point interconnection , characterized in that , it includes steps of:(1) Converting dry biomass wastes into pyrolysis gas, biochar, pyrolysis oil and aqueous condensate by a pyrolyzing unit;(2) Feeding the pyrolysis gas and the aqueous condensate into an anaerobic digestion unit for treating wet biomass wastes;(3) Feeding the biochar into the anaerobic digestion unit wherein the biochar are discharged with digestion residues of the anaerobic digestion unit;(4) Separating the digestion residues into slurry and fiber digestate by a solid-liquid separation unit;(5) Conducting post-treatment on the fiber digestate in a composting unit to form a compost product;(6) Employing heat produced by using the pyrolysis oil and biogas to dry the fiber digestate, the compost and other ...

3-substituted piperidines comprising urea functionality, and methods of use thereof

Heteroaryl compounds and methods of use thereof

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Heterocyclic analgesic compounds and their use

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other the G-protein coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Methods for the stereoselective synthesis of substituted piperidines

Anaerobic immobilized bacterial agent, preparation method for same, and applications thereof

Provided are an anaerobic immobilized bacterial agent, a preparation method for same, and applications thereof. The preparation method for the bacterial agent is: selecting four different anaerobic functional bacterial strains, utilizing a pure bacteria culturing technique to produce corresponding culture broths, then mixing the four culture broths according to a certain volume ratio to acquire a compound functional broth, subsequently concentrating into a functional flora precipitation, then dissolving the functional flora precipitation into a polyvinyl alcohol aqueous solution, dripping the solution into a first buffer solution to produce polyvinyl alcohol gel beads, and placing the gel beads produced into a second sulfate-containing buffer solution to produce sulfate-modified polyvinyl alcohol gel beads, that is, the anaerobic immobilized bacterial agent.

Triple reuptake inhibitors and methods of their use

Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Multicyclic compounds and methods of use thereof.

Se proporcionan en la presente compuestos multicíclicos, métodos de sus síntesis, composiciones farmacéuticas que comprenden los compuestos, y métodos de su uso. Los compuestos proporcionados en la presente son útiles para el tratamiento, prevención, y/o manejo de varios trastornos neurológicos, que incluyen pero no se limitan a, psicosis y esquizofrenia.

Dezocine derivative and medical use thereof

Provided are a dezocine derivative of formula I or a tautomer, optical isomer, oxynitride, solvate, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutical composition comprising the same, a preparation method therefor, and a medical use thereof, the structure of the formula I is as follows:

Antipsychotic sulfonamide-heterocycles, and methods of use thereof

Tetralone-based monoamine reuptake inhibitors

The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.

Pyrrolidine triple reuptake inhibitors

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Heterocyclic analgesic compounds and method of use thereof

One aspect of the present invention relates to novel heterocyclic compounds, such as Formula (1). A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the invention relates to the use of the novel heterocyclic compounds as analgesics.

Cycloalkylamines as monoamine reuptake inhibitors

Pyrrolidine triple reuptake inhibitors

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Heteroaryl compounds and methods of use thereof

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Heteroaryl compounds and methods of use thereof

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Heterocyclic analgesic compounds and their use

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other the G-protein coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Antipsychotic sulfonamide-heterocycles, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.

Multicyclic compounds and methods of use thereof

Disclosed are 7-aminoalkyl-thieno[2,3-c]pyran derivatives and analogues of formula (IVa) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein (i) R1 and R3 together with the atoms to which they are attached form an optionally substituted heterocyclyl, and R4 is hydrogen or alkyl; or (ii) R3 and R4 together form a double bond and together with R1 and the atoms to which they are attached form an optionally substituted 5- to 20-membered heteroaryl; R2 is hydrogen, alkyl or absent; R5 is hydrogen or alkyl; R6 and R7 are each independently (i) hydrogen, halo, alkyl, alkoxyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl, each of which is optionally substituted; or (ii) -(CH2)p-R11, wherein R11 is CF3, CN, nitro, amino (-NH2), hydroxyl, cycloalkoxyl, heteroaryl, or heterocyclyl, each of which is optionally substituted; m is 0, 1, or 2; n is 0, 1, or 2; and each occurrence of p is independently 0, 1, or 2; and wherein the remaining substituents are as defined herein; wherein ‘cycloalkyl’ refers to a cyclic fully or partially saturated bridged and/or non-bridged hydrocarbon radical or ring system; and wherein ‘aminoalkyl’ refers to a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof having one or more N atoms. Representative compounds include 7-(R)-((2S)-pyrrolidin-2-yl)-4,6-dihydro-thieno[2,3-c]pyran, 7-(S)-((2S)-pyrrolidin-2-yl)-4,6-dihydro-thieno[2,3-c]pyran, 7-(R)-((2R)-pyrrolidin-2-yl)-4,6-dihydro-thieno[2,3-c]pyran, 7-(S)-((2R)-pyrrolidin-2-yl)-4,6-dihydro-thieno[2,3-c]pyran, 7-(S)-(imidazol-4-yl)-4,6-dihydro-thieno[2,3-c]pyran and 7-(2-methylpyrazol-3-yl)-4,6-dihydro-thieno[2,3-c]pyran. Also disclosed is a pharmaceutical composition comprising a compounds as defined above, and optionally further comprising one or more additional active agents, for treating a neurological disorder such as schizophrenia, psychotic disorders, Parkinson’s psychosis, Tourette’s syndrome, post- ...

Cycloalkylamines as monoamine reuptake inhibitors

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

4-substituted piperidines, and methods of use thereof

Multicyclic compounds and methods of use thereof

Provided herein are multicyclic compounds, methods or their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

FENY CYCLOAKILAMINES REPLACED AS MONOAMINE RECAPTATION INHIBITORS

Cycloalkylamines as monoamine reuptake inhibitors

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Pyrrolidine triple reuptake inhibitors

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Triple reuptake inhibitors and methods of their use

Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors

PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also disclosed.

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Tetralone-based monoamine reuptake inhibitors

The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.

Carbon-dioxide-responsive self-thickening intelligent fluid based on supramolecular self-assembly

Disclosed is a carbon-dioxide-responsive self-thickening intelligent fluid based on supramolecular self-assembly, which comprises a Gemini surfactant, a single-chain amide molecule having a tertiary amine head group and water, wherein the Gemini surfactant and the single-chain amide molecule are self-assembled to form a vesicle structure dispersed in water, with a hydrophilic head group being located outside and a hydrophobic tail group located inside. The method for preparing the carbon-dioxide-responsive self-thickening intelligent fluid of the present invention is simple, the injection viscosity is low, and the fluid is converted into a gel when encountering carbon dioxide, so that the viscosity is greatly increased.

Carbon-dioxide-responsive self-thickening intelligent fluid based on supramolecular self-assembly

Heteroaryl compounds and methods of use thereof

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Multicyclic compounds and methods of use thereof

Orally-bioavailable formulations of fentanyl and congeners thereof

One aspect of the present invention relates to formulations of fentanyl and its congeners. A second aspect of the present invention relates to the use of the formulations of the present invention as analgesics in mammals.

Method for removing calcium ions from high concentration organic wastewater

A method for removing calcium ions from high concentration organic wastewater is provided. The method comprises the steps of: (1) introducing high concentration organic wastewater containing Ca 2+ , inorganic carbon and a seed crystal into a reactor with a molar ratio of Ca 2+ to inorganic carbon of 1:(3.2-6.2); (2) adjusting the hydrogen ion activity α(H + ) and ionic strength of the solution in the reactor; (3) sequentially stirring and precipitating in the reactor to convert Ca 2+ in the high concentration organic wastewater into calcium carbonate which is then precipitated for calcium removal.

Multicykliske forbindelser og fremgangsmåder til anvendelse deraf

Multisyklisiä yhdisteitä ja niiden käyttömenetelmiä

Carbon-dioxide-responsive self-thickening intelligent fluid based on supramolecular self-assembly

Ligand for a monoamine receptor or transporter for treating addiction or dependence

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapeutically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.